EGFR and neoplasm: In vitro studies demonstrated the superior ability of FcαRI to induce neutrophil-mediated tumor cell killing for multiple tumor antigens, including EGFR, HER2, EpCAM, HLA-II, CD20, CD30, and carcinoembryonic antigen (203, 205, 209).